KRASG12C
52 programs · 50 companies
Programs
52
Companies
50
Active Trials
45
Targeting KRASG12C
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | DMDSCLC | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | MCCSCD | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | Huntington'sFTD | |
| AMG-4531 | Amgen | Phase 2/3 | CLL | |
| REG-8074 | Regeneron | Phase 2/3 | PTSD | |
| VRT-1891 | Vertex Pharma | Phase 1 | Heart FailureNSCLC | |
| Pemitapinarof | BeiGene | Approved | NBFTD | |
| ITC-6153 | Intra-Cellular | Phase 3 | ObesityUrothelial Ca | |
| VIR-5526 | Vir Bio | Phase 3 | HNSCC | |
| EXA-4696 | Exscientia | Phase 2/3 | FSGSMeso | |
| Polalucimab | Bavarian Nordic | Phase 1/2 | LGSCeliac | |
| 450-7627 | Shionogi | Phase 1/2 | Schizophrenia | |
| Bemainavolisib | Evotec | Preclinical | Psoriasis | |
| MEM-IIT-995 | Memorial Sloan Kettering | Preclinical | SMA | |
| SWO-IIT-590 | SWOG | Phase 2/3 | ACC | |
| FRE-IIT-381 | Fred Hutch Cancer Ctr | Phase 2 | FTD | |
| ISO-9327 | Isomorphic Labs | Phase 1 | NBMS | |
| CGE-1556 | Cullinan Onc | Phase 1 | GBMMelanoma | |
| CLL-8422 | Cellectis | Approved | IPFPNH | |
| Nidavorutinib | Abeona | NDA/BLA | Parkinson'sOvarian Ca | |
| ASM-4182 | Assembly Bio | Phase 2 | Ewing Sarcoma | |
| Terarelsin | Replicate Bio | Phase 3 | HSBladder Ca | |
| GLS-7714 | Gelesis | Approved | ALL | |
| EYE-7734 | Eyenovia | Phase 1 | Pompe | |
| DER-3666 | Dermira (Lilly) | Phase 2/3 | SMA | |
| Nidazumab | Forty Seven (Gilead) | Phase 1/2 | MyelofibrosisADPKD | |
| Capizanubrutinib | ABL Bio | Preclinical | Ewing SarcomaCervical Ca | |
| Lisozasiran | JW Therapeutics | Phase 1 | Angelman | |
| TER-8481 | Terray Ther | Phase 1/2 | GBMUrothelial Ca | |
| NER-1837 | Minerva Neuro | Phase 1/2 | Prostate Ca | |
| Riluratamab | Eagle Pharma | Preclinical | CRCNB | |
| 418-7316 | Mitsubishi Tanabe | Phase 2/3 | RAMDD | |
| MEI-1324 | Meiji Pharma | Preclinical | FSGSSMA | |
| 456-4277 | AnGes | Preclinical | PSP | |
| 488-733 | CellSource | Phase 1/2 | Celiac | |
| Tezesacituzumab | Lupin | Phase 1/2 | Bladder Ca | |
| Zanurelsin | Bellus Health (GSK) | Preclinical | T2D | |
| TXM-5550 | TherapeuticsMD | NDA/BLA | ADPKDEpilepsy | |
| Olpaglumide | Laboratorios Rovi | Approved | EpilepsyHNSCC | |
| Bematinib | Bayer AG | Phase 2 | FLMDD | |
| Doxacagene | Camurus | Approved | MesoBCC | |
| Terazanubrutinib | Nanobiotix | Phase 3 | PSPET | |
| EMS-5854 | EMS Pharma | Phase 2 | DLBCLMelanoma | |
| Semafotisoran | EMS Pharma | Phase 1 | RBMigraine | |
| TAB-6074 | Tabuk Pharma | Preclinical | PAHNMOSD | |
| TEV-7734 | Teva Pharma | Approved | FLAML | |
| Doxatenlimab | MindMed | Phase 2 | EoEMCL | |
| Sovainavolisib | Bio-Techne | Preclinical | Obesity | |
| AVT-8949 | Avantor | Phase 3 | PAHAngelman | |
| STA-6220 | Stada Arzneimittel | Phase 1 | RSVMS | |
| GR-8075 | Grünenthal | Preclinical | RettHCC | |
| DEF-8311 | Definiens | Phase 1/2 | Urothelial CaCeliac |